BRISBANE, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces they will have a significant presence at the Cutting Edge of Transplantation (CEoT) meeting in Phoenix, Arizona, February 8-10, 2018.
CareDx is hosting a symposium titled “Innovation in Allograft Health Surveillance: Clinical Implementation of Cell-Free DNA Testing for Transplant Patients,” including the following speakers:
- Moving molecular diagnostics from bench to bedside: Clinical implementation in kidney transplant patients
Peter S. Heeger, M.D., Professor of Medicine, Director of Transplant Research, Icahn School of Medicine at Mount Sinai
- Early clinical experience with AlloSure in kidney transplant patients
Matthew Weir, M.D., Professor of Medicine, Director of the Division of Nephrology, University of Maryland School of Medicine
- Implementation of AlloSure into clinical practice
Alexander Wiseman, M.D., Professor of Medicine, Medical Director, Renal and Transplant Programs, University of Colorado
- Clinical application of donor-derived cfDNA testing for heart transplant surveillance
Jon A. Kobashigawa, M.D., Thomas D. Gordon, Professor of Medicine, and Director of the Heart Transplant Program, Cedars-Sinai Medical Center
“CEoT is a great forum for companies like CareDx and transplant professionals to interface and learn about cutting-edge science and research in an educational setting in order to bridge the gap from basic to translational to clinical science,” said Dr. Ronald Gill, AST President. “CareDx’s sponsored lunch symposium at CEoT, ‘Innovation in Allograft Health Surveillance: Clinical Implementation of Cell-Free DNA Testing for Transplant Patients,’ will provide education on this important topic to the kidney transplant community.”
CareDx’s President & CEO, Peter Maag, is participating in the Clinical Therapeutics to Improve Patient Outcomes - The Tribulations of Trials in Transplantation panel discussion at CEoT on Saturday, February 10.
Additionally, CareDx will have a booth in the exhibit hall and the following scientific posters featuring CareDx transplant surveillance solutions:
- Donor-Derived Cell Free DNA May Detect Antibody-Mediated Rejection After Heart Transplantation – Jon A. Kobashigawa, MD, et al.
- Gene Expression Profile Testing Scores Are Associated with New Onset Coronary Allograft Vasculopathy – Preethi Pirlamarla, MD, et al.
The American Society of Transplantation is an organization of professionals dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation.
Founded in 1982, the American Society of Transplantation (AST) is an organization of more than 3,500 professionals dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation. The society is the largest transplant organization in North America and is recognized as the premier society for transplantation. AST members are sought out as transplant experts and advocates. Other transplant organizations, policy makers, regulatory agencies, payors, academic institutions, and the general public look to the AST for guidance, research, and resources related to transplantation.
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap and AlloSure for post-transplant surveillance, and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA typing.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed by us with the SEC on April 21, 2017 and the periodic reports that we have subsequently filed with the SEC. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Commercial Officer
Integrated Corporate Relations, Inc.